Welcome to our dedicated page for Intelligent Bio Solutions news (Ticker: INBS), a resource for investors and traders seeking the latest updates and insights on Intelligent Bio Solutions stock.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company focused on intelligent, rapid, non-invasive testing solutions, with a primary emphasis on its Intelligent Fingerprinting Drug Screening System. The INBS news feed on Stock Titan aggregates company announcements, press releases and related coverage so readers can follow developments around its fingerprint-based drug screening platform, partnerships and capital markets activity.
Recent news highlights include record fiscal 2026 first quarter revenue driven by consumable cartridge sales, the addition of dozens of new customer accounts across more than 24 countries, and large deployments with organizations in sectors such as industrial services and public transport. Updates also cover the company’s razor–razor-blade business model, where installed readers support recurring cartridge revenue, and its efforts to expand adoption in safety-critical industries like construction, manufacturing and engineering, transport and logistics, mining and government administration.
INBS news items frequently address strategic partnerships and manufacturing, such as the collaboration with Syrma Johari MedTech Ltd to scale production of the Intelligent Fingerprinting Drug Screening Reader, and the alliance with Vlepis Pty Ltd to explore wearable patch technologies and consumer health monitoring. Additional coverage includes the distribution agreement for the SmarTest Patch, a 7–10 day continuous drug monitoring solution, and updates on regulatory pathways, including anticipated FDA 510(k) submissions.
Investors can also track capital structure and listing-related developments, including reverse stock split decisions, Nasdaq bid price deficiency notices and private placement financings with institutional investors. By reviewing the INBS news stream, readers gain context on how Intelligent Bio Solutions is executing its commercial strategy, expanding its customer base, managing manufacturing partnerships and addressing regulatory and listing requirements over time. Bookmark this page to quickly access the latest official communications and market-moving updates related to INBS.
Intelligent Bio Solutions (NASDAQ: INBS) confirmed first shipment and deployment of readers manufactured with Syrma Johari, validating scaled production and ISO 13485/MDSAP compliance. The partnership increases reader capacity ~4x and is on track to deliver >40% annual production cost savings, targeting ~20 percentage-point gross margin improvement. INBS also doubled in-house lateral flow strip capacity, improving vertical integration, R&D speed, and enabling expanded drug-panel cartridges ahead of planned U.S. market entry in 2026.
Intelligent Bio Solutions (Nasdaq: INBS) announced a partnership with Bouygues UK, a subsidiary of Bouygues Construction, to deploy INBS’s fingerprint drug screening across 13 UK project sites. Bouygues Construction reported a turnover of €10.3 billion in 2024 and employs 35,600 globally. According to the company, a joint ROI analysis showed substantial cost savings versus third-party testing, and the UK rollout is positioned as a foundation for potential wider expansion across Bouygues operations.
Intelligent Bio Solutions (Nasdaq: INBS) reported fiscal Q2 revenue of $896,774, up 48% YoY, and six‑month revenue of $2.01M, up 36% YoY. Reader sales surged 104% YoY to $246,519 in Q2; cartridges rose 33% YoY to $516,754.
Gross profit margin for H1 fiscal 2026 improved to 49% (from 39%). The company closed a $10.0M private placement (net proceeds $9.40M received Jan 2, 2026) and announced manufacturing and commercial partnerships while advancing FDA 510(k) studies.
Intelligent Bio Solutions (Nasdaq: INBS) expects preliminary unaudited fiscal Q2 2026 revenue to rise about 48% YoY, and fiscal H1 2026 total revenue to be approximately $2.01 million (up 36% YoY).
Reader sales are expected to increase ~104% YoY in Q2 while cartridge sales are up ~33% Q2 / 38% H1, with accessories/training also growing. Results are preliminary and subject to quarter-end close and Form 10-Q filing during the week of Feb 9, 2026.
Intelligent Bio Solutions (Nasdaq: INBS) initiated clinical studies on Jan 28, 2026 to support an FDA 510(k) submission for its Intelligent Fingerprinting Drug Screening System targeting codeine detection.
The first cohort (40 adults) will use the DSR-Plus reader and fingerprint cartridges, include LC-MS/MS confirmation and predicate-device comparisons; full data analysis is expected by end of March 2026 for incorporation into the 510(k) package.
Intelligent Bio Solutions (Nasdaq: INBS) closed a private placement priced at-the-market, selling 2,298,850 common shares (or pre-funded warrants) plus Series K-1 and K-2 warrants to purchase up to 2,298,850 shares each, for combined gross proceeds of approximately $10.0 million before fees.
The common shares (or pre-funded warrants) and associated warrants were sold at $4.35 per unit; the warrants have an exercise price of $4.10, are exercisable immediately, and will have a five-year term following effectiveness of a registration statement. Proceeds are intended for working capital, general corporate purposes and to fund a 510(k) FDA submission. The company agreed to file a resale registration within 10 days and use best efforts to have it declared effective within 45 days.
Intelligent Bio Solutions (Nasdaq: INBS) entered a private placement to raise approximately $10.0 million in gross proceeds by selling 2,298,850 common shares (or pre-funded warrants) and issuing Series K-1 and K-2 warrants exercisable to purchase up to an additional 2,298,850 shares each at a $4.10 exercise price.
The securities are being sold at a combined purchase price of $4.35 per share (or pre-funded warrant) plus associated warrants, with closing expected on or about January 2, 2026. Ladenburg Thalmann is the exclusive placement agent. Proceeds are intended for working capital and general corporate purposes. The company will file a resale registration statement within 10 calendar days and aims for effectiveness no later than 45 days after the agreement.
Intelligent Bio Solutions (Nasdaq: INBS) announced a strategic manufacturing partnership with Syrma Johari MedTech to scale production of its Intelligent Fingerprinting Drug Screening Reader ahead of planned U.S. market entry in 2026.
The collaboration is expected to deliver >40% annual production cost savings, an ~20 percentage‑point improvement in gross margin versus the prior arrangement, and ~4x current manufacturing capacity through Syrma Johari’s 14 facilities and 1.1M+ sq ft footprint. Syrma Johari holds ISO 13485, MDSAP, FDA, TUV SUD, and GMP certifications to support global regulatory needs.
Intelligent Bio Solutions (Nasdaq: INBS) announced a non-exclusive strategic alliance with Vlepis on Dec 18, 2025 to collaborate on R&D, distribution, and regulatory work for non-invasive testing and wearable patch technologies.
The partnership aims to extend INBS’ Intelligent Fingerprinting and SMARTOX SmarTest Patch into consumer health monitoring, leveraging Vlepis’ wearable sensors and cloud/mobile connectivity to accelerate international commercialization and broaden revenue opportunities.
Intelligent Bio Solutions (Nasdaq: INBS) will effect a 1‑for‑10 reverse stock split at 11:59 PM ET on December 15, 2025, with split‑adjusted trading resuming on Nasdaq at the open on December 16, 2025 under the symbol INBS and new CUSIP 36151G709.
The split was approved by stockholders on October 16, 2025; every 10 shares issued and outstanding will be combined into one share and outstanding equity awards and warrants will be proportionately adjusted. No fractional shares will be issued; holders entitled to fractions will receive a cash payment in lieu of a fractional share. Par value remains $0.01 and authorized shares remain at 100,000,000. Immediately after the reverse split, approximately 959,533 shares will be issued and outstanding.